Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464827 · ClinicalTrials.gov registry record · Phase 2
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 580
- Enrollment target
NCT01464827 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 580 participants.
The verdict
NCT01464827, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 580 participants
- Enrollment target
Study Summary
This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).
Interventions
- DRUG Ritonavir
- DRUG Ribavirin
- DRUG ABT-450
- DRUG ABT-333
- DRUG ABT-267
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464827
The ClinicalTrials.gov registry entry for NCT01464827 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ritonavir is the first listed.
NCT01464827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01464827 about?
NCT01464827 is a clinical study titled "ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients". This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).
What is the current status of trial NCT01464827?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 580 participants. The study started on 2011-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01464827?
The interventions under investigation include: Ritonavir (DRUG), Ribavirin (DRUG), ABT-450 (DRUG), ABT-333 (DRUG), ABT-267 (DRUG).
Who is sponsoring clinical trial NCT01464827?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.